Fundraising Fox
/Companies
Sign in

Clostrabio

Chicago, US · Founded 2016 · Delaware corporation · 13 employees on LinkedIn · 2 known investors

Find your way into Clostrabio

Sign up to see every warm intro you have to Clostrabio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Clostrabio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.

BiotechDigital HealthHealthtech

Founders & leadership

Clostrabio was founded in 2016 by Jeffrey Hubbell and Cathryn Nagler.

JH
Jeffrey HubbellSecretary
CNCathryn Nagler
Cathryn NaglerCo-FounderShe has spent a decade researching how the commensal microbiota regulates immune responses to food antigens, work conducted through antibiotic-treated and gnotobiotic mouse models, and is now translating these findings into microbiome-modulating therapeutic development.
BN
Brett NewswangerChief Operating Officer

Board

JFJohn Flavin
John FlavinExecutive ChairmanGeneral Partner at Portal Innovations Momentum

Investors · 2

Stone Mountain Ventureslisted by Stone Mountain VenturesDallas · $5Mvia John Diaz · inferred

How we know: Stone Mountain Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$9.9M disclosed across 1 round · 2022

▶$9.9MraisedSep 2022 · 15 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Brett NewswangerExecutive Officer
  • Jeffrey HubbellExecutive Officer, Director
  • Cathryn NaglerExecutive Officer, Director
  • John FlavinExecutive Officer, Director
Offering amount
$11M
Amount sold
$9.9M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Clostrabio went on to found or lead other companies.

Matt MartinVP OperationsFounded Saros TherapeuticsJohn FlavinExecutive ChairmanFounded Portal Innovations

Related companies · 1

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as Clostrabio.

Frequently asked questions

What does Clostrabio do?
ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.
Who founded Clostrabio?
Clostrabio was founded by Jeffrey Hubbell, Cathryn Nagler in 2016.
Who are Clostrabio's investors?
Clostrabio's investors include Portal Innovations, Stone Mountain Ventures.
How much funding has Clostrabio raised?
Clostrabio has disclosed $9.9M raised across 1 round.
Where is Clostrabio headquartered?
Clostrabio is headquartered in Chicago, US.